Diagnostic performance of aPS/PT antibodies in neuropsychiatric lupus and cardiovascular complications of systemic lupus erythematosus

References

• Fernandez-Gutierrez B, Perrotti PP, Gisbert JP, et al. Cardiovascular disease in immune-mediated inflammatory diseases: a cross-sectional analysis of 6 cohorts. Medicine (Baltimore). 2017;96:e7308.
   PubMed Web of Science ®Google Scholar
• Scalzi LV, Hollenbeak CS, Wang L. Racial disparities in age at time of cardiovascular events and cardiovascular-related death in patients with systemic lupus erythematosus. Arthritis Rheum. 2010;62:2767–2775.
   PubMed Web of Science ®Google Scholar
• Bakshi J, Segura BT, Wincup C, et al. Unmet needs in the pathogenesis and treatment of systemic lupus erythematosus. Clinic Rev Allerg Immunol. 2018;55:352–357.
   PubMed Web of Science ®Google Scholar
• Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol. 2012;176:708–719.
   PubMed Web of Science ®Google Scholar
• Joseph JE, Harrison P, Mackie IJ, et al. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol. 2001;115:451–459.
   PubMed Web of Science ®Google Scholar
• Tyden H, Lood C, Gullstrand B, et al. Endothelial dysfunction is associated with activation of the type I interferon system and platelets in patients with systemic lupus erythematosus. RMD Open. 2017;3:e000508.
   PubMed Web of Science ®Google Scholar
• Mason JC. Cytoprotective pathways in the vascular endothelium. Do they represent a viable therapeutic target? Vascul Pharmacol. 2016;86:41–52.
   PubMed Web of Science ®Google Scholar
• Tselios K, Gladman DD, Su J, et al. Evolution of risk factors for atherosclerotic cardiovascular events in systemic lupus erythematosus: a longterm prospective study. J Rheumatol. 2017;44:1841–1849.
   PubMed Web of Science ®Google Scholar
• Escarcega RO, Garcia-Carrasco M, Jara LJ, et al. Accelerated atherosclerosis in systemic lupus erythematosus: perspectives towards decreasing cardiovascular morbidity and mortality. Lupus. 2009;18:383–386.
   PubMed Web of Science ®Google Scholar
• Cervera R, Serrano R, Pons-Estel GJ, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;74:1011–1018.
   PubMed Web of Science ®Google Scholar
• Bertolaccini ML, Sanna G. Recent advances in understanding antiphospholipid syndrome. F1000Res. 2016;5:2908.
   PubMedGoogle Scholar
• Pons-Estel GJ, Andreoli L, Scanzi F, et al. The antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun. 2017;76:10–20.
   PubMed Web of Science ®Google Scholar
• Chighizola CB, Raschi E, Borghi MO, et al. Update on the pathogenesis and treatment of the antiphospholipid syndrome. Curr Opin Rheumatol. 2015;27:476–482.
   PubMed Web of Science ®Google Scholar
• Arachchillage DR, Efthymiou M, Mackie IJ, et al. Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome. J Thromb Haemost. 2014;12:1801–1809.
   PubMed Web of Science ®Google Scholar
• Hoxha A, Mattia E, Tonello M, et al. Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome. Clin Chem Lab Med. 2017;55:890–898.
   PubMed Web of Science ®Google Scholar
• Sciascia S, Sanna G, Murru V, et al. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost. 2014;111:354–364.
   PubMed Web of Science ®Google Scholar
• Zigon P, Cucnik S, Ambrozic A, et al. Detection of antiphosphatidylserine/prothrombin antibodies and their potential diagnostic value. Clin Dev Immunol. 2013;2013:724592.
   PubMedGoogle Scholar
• Canti V, Del Rosso S, Tonello M, et al. Antiphosphatidylserine/prothrombin antibodies in patients with anti-phospholipid syndrome with intrauterine growth restriction and preeclampsia. J Rheumatol. 2018;45:1263–1272.
   PubMed Web of Science ®Google Scholar
• Syuto T, Shimizu A, Takeuchi Y, et al. Association of antiphosphatidylserine/prothrombin antibodies with neuropsychiatric systemic lupus erythematosus. Clin Rheumatol. 2009;28:841–845.
   PubMed Web of Science ®Google Scholar
• Sciascia S, Sanna G, Murru V, et al. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford). 2013;52:1397–1403.
   PubMed Web of Science ®Google Scholar
• Petri M, Magder LS. Systemic lupus erythematosus cardiovascular risk equation. ACR Annual Scientific Meeting. 2009.
   Google Scholar
• Urowitz MB, Ibanez D, Su J, et al. Modified Framingham risk factor score for systemic lupus erythematosus. J Rheumatol. 2016;43:875–879.
   PubMed Web of Science ®Google Scholar
• Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.
   PubMed Web of Science ®Google Scholar
• ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599–608.
   PubMed Web of Science ®Google Scholar
• Bortoluzzi A, Scire CA, Bombardieri S, et al. Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology (Oxford). 2015;54:891–898.
   PubMed Web of Science ®Google Scholar
• D'Agostino RB, Sr., Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743–753.
   PubMed Web of Science ®Google Scholar
• D'agostino RB, Pencina MJ. Cardiovascular disease (10-year risk). [accessed 2015 Jan 1]. Available from: https://www.framinghamheartstudy.org/fhs-risk-functions/cardiovascular-disease-10-year-risk/
   Google Scholar
• Ruiz-Irastorza G, Egurbide MV, Ugalde J, et al. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med. 2004;164:77–82.
   PubMedGoogle Scholar
• Borba EF, Araujo DB, Bonfa E, et al. Clinical and immunological features of 888 Brazilian systemic lupus patients from a monocentric cohort: comparison with other populations. Lupus. 2013;22:744–749.
   PubMed Web of Science ®Google Scholar
• Sciascia S, Murru V, Sanna G, et al. Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost. 2012;10:2512–2518.
   PubMed Web of Science ®Google Scholar
• Nojima J, Kuratsune H, Suehisa E, et al. Anti-prothrombin antibodies combined with lupus anti-coagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus. Br J Haematol. 2001;114:647–654.
   PubMed Web of Science ®Google Scholar
• Nojima J, Iwatani Y, Suehisa E, et al. The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus. Haematologica. 2006;91:699–702.
   PubMed Web of Science ®Google Scholar
• Pengo V, Denas G, Bison E, et al. Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA). Thromb Res. 2010;126:150–153.
   PubMed Web of Science ®Google Scholar
• Pregnolato F, Chighizola CB, Encabo S, et al. Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS? Immunol Res. 2013;56:432–438.
   PubMed Web of Science ®Google Scholar
• Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827–1832.
   PubMed Web of Science ®Google Scholar
• Bertolaccini ML, Sciascia S, Murru V, et al. Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS/PT) in patients with and without lupus anticoagulant. Thromb Haemost. 2013;109:207–213.
   PubMed Web of Science ®Google Scholar
• Antovic A, Norberg EM, Berndtsson M, et al. Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting. Thromb Haemost. 2017;117:1700–1704.
   PubMed Web of Science ®Google Scholar
• Shi H, Zheng H, Yin YF, et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome. Clin Chem Lab Med. 2018;56 :614–624.
   PubMed Web of Science ®Google Scholar
• Unterman A, Nolte JE, Boaz M, et al. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2011;41:1–11.
   PubMed Web of Science ®Google Scholar
• Baqai T, Isenberg DA, Ioannou Y. Pathogenesis of neurocognitive and neuropsychiatric manifestations in childhood-onset lupus: an overview. Rheumatol Rep. 2014;5:6.
   Google Scholar
• Fanouriakis A, Boumpas DT, Bertsias GK. Pathogenesis and treatment of CNS lupus. Curr Opin Rheumatol. 2013;25:577–583.
   PubMed Web of Science ®Google Scholar
• Ho RC, Ong H, Thiaghu C, et al. Genetic variants that are associated with neuropsychiatric systemic lupus erythematosus. J Rheumatol. 2016;43:541–551.
   PubMed Web of Science ®Google Scholar
• Faria R, Goncalves J, Dias R. Neuropsychiatric systemic lupus erythematosus involvement: towards a tailored approach to our patients? Rambam Maimonides Med J. 2017;8:e0001.
   Web of Science ®Google Scholar
• Clark KE, Clark CN, Rahman A. A critical analysis of the tools to evaluate neuropsychiatric lupus. Lupus. 2017;26:504–509.
   PubMed Web of Science ®Google Scholar
• Zardi EM, Taccone A, Marigliano B, et al. Neuropsychiatric systemic lupus erythematosus: tools for the diagnosis. Autoimmun Rev. 2014;13:831–839.
   PubMed Web of Science ®Google Scholar
• Govoni M, Bortoluzzi A, Padovan M, et al. The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J Autoimmun. 2016;74:41–72.
   PubMed Web of Science ®Google Scholar
• Coin MA, Vilar-Lopez R, Peralta-Ramirez I, et al. The role of antiphospholipid autoantibodies in the cognitive deficits of patients with systemic lupus erythematosus. Lupus. 2015;24:875–879.
   PubMed Web of Science ®Google Scholar
• Kozora E, Erkan D, Zhang L, et al. Cognitive dysfunction in antiphospholipid antibody (aPL)-negative systemic lupus erythematosus (SLE) versus aPL-positive non-SLE patients. Clin Exp Rheumatol. 2014;32:34–40.
   PubMed Web of Science ®Google Scholar
• Nossent J, Cikes N, Kiss E, et al. Current causes of death in systemic lupus erythematosus in Europe, 2000–2004: relation to disease activity and damage accrual. Lupus. 2007;16:309–317.
   PubMed Web of Science ®Google Scholar
• Tsang A, Bultink IE, Heslinga M, et al. Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus. Rheumatology (Oxford). 2017;56:121–128.
   PubMed Web of Science ®Google Scholar